Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
- Conditions
- Spinal Muscular Atrophy (SMA)
- Interventions
- Other: Prospective observational registry
- Registration Number
- NCT04174157
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases.
The purpose of this registry is to assess the long term outcomes of patients with SMA in the context of advances in treatment options and also to characterize and assess long-term safety and effectiveness of OAV-101.
- Detailed Description
This is a prospective, multi center, multinational, non-interventional observational study. All patients will be managed according to the clinical site's normal clinical practice, i.e., the diagnostic and clinical treatment/practice process that a clinician chooses according to their clinical judgement for an SMA patient. Clinical care will not be driven by the protocol. No additional visits or investigations will be performed beyond normal clinical practice. Patients will be followed for 15 years from enrolment or until death, whichever is sooner.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 700
- Patients treated with OAV-101 with a genetically confirmed diagnosis of SMA regardless of the date of diagnosis.
- Appropriate consent/assent has been obtained for participation in the registry
- Currently enrolled in an interventional clinical trial involving an investigational medicinal product to treat SMA.
Note: Patients who are participating in a Compassionate Use Program (CUP) for OAV-101 (Zolgensma) such as a Managed Access Program (MAP), an Expanded Access Program (EAP), Single Patient Investigational New Drug (IND) (SPI) or Named Patient Program (NPP) are eligible to enroll in the registry regardless of the date of a genetic or clinical diagnosis of SMA.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Prospective observational registry Prospective observational registry This is a prospective, multi center, multinational, non-interventional observational registry. Prospective observational registry Zolgensma This is a prospective, multi center, multinational, non-interventional observational registry.
- Primary Outcome Measures
Name Time Method Incidence of treatment emergent serious adverse events Through 15 years of follow up Change in probability of survival of all patients with SMA using Kaplan Meier method to estimate Based on information collected at Baseline and every 6 months through 2 years of follow-up, then annually through 15 years of follow up. Incidence of treatment emergent adverse events Through 15 years of follow up Change from baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) for patients with type II and III SMA Baseline and every 6months through 2 years of follow up, then annually through 15 years of follow up HFMSE score range from 0 to 66 with the higher scores indicating more development.
Incidence of treatment emergent thrombocytopenia, hepatotoxicity and cardiac adverse events Through 15 years of follow up Incidence of treatment emergent adverse events related to therapy Through 15 years of follow up Change from baseline Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) in infants with pre-symptomatic or type I SMA Baseline and every 6 months through 2 years of follow up, then annually through 15 years of follow up CHOP INTEND score ranges from 0 to 64 with higher scores indicating higher motor function
Change from baseline Hammersmith Infant Neurological Examination (HINE) in infants with pre-symptomatic, type I or type II SMA Baseline and every 6 months through 2 years of follow up, then annually through 15 years of follow up HINE score range from 0 to 26 with higher scores indicating more development.
- Secondary Outcome Measures
Name Time Method Change from baseline in Zarit Burden Interview Baseline and every 6 months through 2 years of follow up, then annually through 15 years of follow up Zarit Burden Total Score ranges from 0 to 88. A higher score correlates with higher level of burden.
Change from baseline in PedsQL Patient interview Baseline and every 6 months through 2 years of follow up, then annually through 15 years of follow up PedsQL Total Scale Score is average of all items and ranges from 0 to 100. A higher score correlates with better Health-Related Quality of Life
Change from baseline in PedsQL Parent interview Baseline and every 6 months through 2 years of follow up, then annually through 15 years of follow up PedsQL Total Scale Score is average of all items and ranges from 0 to 100. A higher score correlates with better Health-Related Quality of Life
Change from baseline in percent of patients requiring ventilator support (BiPAP, Endotracheal tube) : Baseline and every 6 months through 2 years of follow up, then annually through 15 years of follow up Change from baseline in rates of hospitalization Baseline and every 6 months through 2 years of follow up, then annually through 15 years of follow up Change from baseline in in percent of patients requiring mobility device support (Ankle-Foot Orthoses, Supramalleolar Orthosis, Orthotic/shoe inserts, Knee immobilizers, Knee-Ankle-Foot Orthoses , Hand splints, Spinal bracing) : Baseline and every 6 months through 2 years of follow up, then annually through 15 years of follow up Change from baseline in in percent of patients requiring nutritional support (Gastrostomy Tube, Gastrojejunal tube (GT) with Nissen fundoplication, GT without Nissen fundoplication, Nasogastrictube, Nasojejunaltube or Percutaneous endoscopic gastrostomy) Baseline and every 6 months through 2 years of follow up, then annually through 15 years of follow up
Trial Locations
- Locations (99)
Penteli Children's Hospital
🇬🇷Penteli, Attikis, Greece
St. Sophia Children's Hospital
🇬🇷Thessaloniki, Greece
Nikko Memorial Hospital
🇯🇵Hokkaido, Japan
Dokkyo Medical University Saitama Medical Center
🇯🇵Saitama, Japan
Seoul National University Children's Hospital
🇰🇷Seoul, Korea, Republic of
Samsung Medical Centre
🇰🇷Seoul, Korea, Republic of
Yongin Severance Hospital
🇰🇷Yongin-si, Korea, Republic of
Uniwersytecki Szpital Dzieciec
🇵🇱Lublin, Poland
CHUC - Hospital Pediatrico
🇵🇹Coimbra, Portugal
Centro Hospitalar Universitaria de Lisboa Central, EPE
🇵🇹Lisboa, Portugal
Scroll for more (89 remaining)Penteli Children's Hospital🇬🇷Penteli, Attikis, GreeceChrysanthi TsimakidiContact